Activation of lymphocytes by anti-CD3 single-chain antibody dimers expresses' on the plasma membrane of tumor cells

Gene Therapy

Volumn 7, Issue 4, 2000, Pages 339-347

  Liao, K W ^a,b   Lo, Y C ^b   Roffler, S R ^b  

^a NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^b INSTITUTE OF BIOMEDICAL SCIENCES   (Taiwan)

Author keywords

CD3; Chimeric protein; Gene therapy; Immunotherapy; Single chain antibody; Transmembrane

Indexed keywords

ANTIBODY; B7 ANTIGEN; CD3 ANTIGEN; CHIMERIC PROTEIN; DISULFIDE; IMMUNOGLOBULIN G1; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN BINDING; ANTIGEN PRESENTATION; ARTICLE; CELL KILLING; CELL MEMBRANE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; LYMPHOCYTE ACTIVATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROVOCATION TEST; SPLEEN CELL; T LYMPHOCYTE ACTIVATION; TUMOR CELL;

ANIMALIA; MURINAE;

EID: 0034003314     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301080     Document Type: Article

References (42)

1. Urban JL, Schreiber H. Tumor antigens. Annu Rev Immunol 1992; 10: 617-644.
2. Wang RF. Tumor antigens discovery: perspectives for cancer therapy. Mol Med 1997; 3: 716-731.
3. Goldberg AL, Rock KL. Proteolysis, proteasomes and antigen presentation. Nature 1992; 357: 375-379.
4. Maeurer MJ et al. Tumor escape from immune recognition: loss of HLA-A2 melanoma cell surface expression is associated with a complex rearrangement of the short arm of chromosome 6. Clin Cancer Res 1996; 2: 641-652.
5. Blades RA et al. Loss of HLA class I expression in prostate cancer: implications for immunotherapy. Urology 1995; 46: 681-686.
6. Korkolopoulou P et al. Loss of antigen-presenting molecules (MHC class I and TAP-1) in lung cancer. Br J Cancer 1996; 73: 148-153.
7. Nouri AM, Hussain RF, Oliver RT. The frequency of major histocompatibility complex antigen abnormalities in urological tumours and their correction by gene transfection or cytokine stimulation. Cancer Gene Ther 1994; 1: 119-123.
8. Luboldt HJ, Kubens BS, Rubben H, Grosse Wilde H. Selective loss of human leukocyte antigen class I allele expression in advanced renal cell carcinoma. Cancer Res 1996; 56: 826-830.
9. Kaklamanis L et al. Loss of major histocompatibility complex-encoded transporter associated with antigen presentation (TAP) in colorectal cancer. Am J Pathol 1994; 145: 505-509.
10. Vitale M et al. HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res 1998; 58: 737-742.
11. Restifo NP et al. Loss of functional beta 2-microglobulin in metastatic melanomas from five patients receiving immunotherapy. J Natl Cancer Inst 1996; 88: 100-108.
12. Moritz D, Wels W, Mattern J, Groner B. Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 1994; 91: 4318-4322.
13. Altenschmidt U, Moritz D, Groner B. Specific cytotoxic T lymphocytes in gene therapy. J Mol Med 1997; 75: 259-266.
14. Altenschmidt U, Klundt E, Groner B. Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression. J Immunol 1997; 159: 5509-5515.
15. Alvarez Vallina L, Agha Mohammadi S, Hawkins RE, Russell SJ. Pharmacological control of antigen responsiveness in genetically modified T lymphocytes. J Immunol 1997; 159: 5889-5895.
16. Bolhuis RL, Sturm E, Braakman E. T cell targeting in cancer therapy. Cancer Immunol Immunother 1991; 34: 1-8.
17. Tibben JG et al. Pharmacokinetics, biodistribution and biological effects of intravenously administered bispecific monoclonal antibody OC/TR F(ab′)2 in ovarian carcinoma patients. Int J Cancer 1996; 66: 477-483.
18. Weiner LM, Clark JI, Ring DB, Alpaugh RK. Clinical development of 2B1, a bispecific murine monoclonal antibody targeting c-erbB-2 and Fc gamma RIII. J Hematother 1995; 4: 453-456.
19. Chou WC et al. Expression of chimeric monomer and dimer proteins on the plasma membrane of mammalian cells. Biotechnol Bioeng 1999; 65: 160-169.
20. Reddy P, Caras I, Krieger M. Effects of O-linked glycosylation on the cell surface expression and stability of decay-accelerating factor, a glycophospholipid-anchored membrane protein. J Biol Chem 1989; 264: 17329-17336.
21. Kozarsky K, Kingsley D, Krieger M. Use of a mutant cell line to study the kinetics and function of O-linked glycosylation of low density lipoprotein receptors. Proc Natl Acad Sci USA 1988; 85: 4335-4339.
22. Freeman GJ et al. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J Exp Med 1991; 174: 625-631.
23. Minami Y, Kono T, Miyazaki T, Taniguchi T. The IL-2 receptor complex: its structure, function, and target genes. Annu Rev Immunol 1993; 11: 245-268.
24. Shahinian A et al. Differential T cell costimulatory requirements in CD28-deficient mice. Science 1993; 261: 609-612.
25. Van Seventer GA, Shimizu Y, Morgan KJ, Shaw S. The LFA-1 ligand ICAM-1 provides an important costimulatory signal for T cell receptor-mediated activation of resting T cells. J Immunol 1990; 144: 4579-4586.
26. von Leoprechting A et al. Stimulation of CD40 on immunogenic human malignant melanomas augments their cytotoxic T lymphocyte-mediated lysis and induces apoptosis. Cancer Res 1999; 59: 1287-1294.
27. Viola A, Schroeder S, Sakakibara Y, Lanzavecchia A. T lymphocyte costimulation mediated by reorganization of membrane microdomains. Science 1999; 283: 680-682.
28. + T cells independently of the CD28/B7 and LFA-1/ICAM-1 costimulatory interactions. J Immunol 1998; 160: 3180-3187.
29. Viola A, Lanzavecchia A. T cell activation determined by T cell receptor number and tunable thresholds. Science 1996; 273: 104-106.
30. Harding CV, Unanue ER. Quantitation of antigen-presenting cell MHC class II/peptide complexes necessary for T cell stimulation. Nature 1990; 346: 574-576.
31. Kroesen BJ et al. Approaches to lung cancer treatment using the CD3 × EGP-2-directed bispecific monoclonal antibody BIS-1. Cancer Immunol Immunother 1997; 45: 203-206.
32. Bolhuis RL et al. Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. Int J Cancer 1992; 7 (Suppl): 78-81.
33. Kroesen BJ et al. Phase I study of intravenously applied bispecific antibody in renal cell cancer patients receiving subcutaneous interleukin 2. Br J Cancer 1994; 70: 652-661.
34. Blank Voorthuis CJ et al. Clustered CD3/TCR complexes do not transduce activation signals after bispecific monoclonal antibody-triggered lysis by cytotoxic T lymphocytes via CD3. J Immunol 1993; 151: 2904-2914.
35. Wang RF et al. Recognition of an antigenic peptide derived from tyrosinase-related protein-2 by CTL in the context of HLA-A31 and -A33. J Immunol 1998; 160: 890-897.
36. Jantzer P, Schendel DJ. Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo. Cancer Res 1998; 58: 3078-3086.
37. Winberg G et al. Surface expression of CD28 single chain Fv for costimulation by tumor cells. Immunol Rev 1996; 153: 209-223.
38. Hayden MS et al. Costimulation by CD28 sFv expressed on the tumor cell surface or as a soluble bispecific molecule targeted to the L6 carcinoma antigen. Tissue Ant 1996; 48: 242-254.
39. Maloney DG et al. Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro. Hybridoma 1985; 4: 191-209.
40. Pear WS, Nolan GP, Scott ML, Baltimore D. Production of high-titer helper-free retroviruses by transient transfection. Proc Natl Acnd Sci USA 1993; 90: 8392-8396.
41. Belnap LP et al. Immunogenicity of chemically induced murine colon cancers. Cancer Res 1979; 39: 1174-1179.
42. Solar I, Gershoni JM. Linker modification introduces useful molecular instability in a single chain antibody. Protein Eng 1995; 8: 717-723.